Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19
© Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024..
Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2024) vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shah, Melisa M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Covid-19 |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciae105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369015789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369015789 | ||
| 003 | DE-627 | ||
| 005 | 20240229165615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciae105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM369015789 | ||
| 035 | |a (NLM)38411622 | ||
| 035 | |a (PII)ciae105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shah, Melisa M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024. | ||
| 520 | |a Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a nirmatrelvir-ritonavir | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Joyce, Brendan |e verfasserin |4 aut | |
| 700 | 1 | |a Plumb, Ian D |e verfasserin |4 aut | |
| 700 | 1 | |a Sahakian, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Feldstein, Leora R |e verfasserin |4 aut | |
| 700 | 1 | |a Barkley, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Paccione, Mason |e verfasserin |4 aut | |
| 700 | 1 | |a Deckert, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Sandmann, Danessa |e verfasserin |4 aut | |
| 700 | 1 | |a Hagen, Melissa Briggs |e verfasserin |4 aut | |
| 700 | 1 | |a Gerhart, Jacqueline L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2024) vom: 27. Feb. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciae105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 02 | ||